This is a prospective, open-label, single-center, single-arm phase II clinical trial evaluating the efficacy and safety of multimodal ablation in combination with perioperative tislelizumab and chemotherapy in patients with pathologically confirmed resectable stage II-IIIB (N2) non-small cell lung cancer (NSCLC).
Age >= 18 years, either gender;
Pathologically confirmed stage II-IIIB (N2) squamous or non-squamous non-small cell lung cancer (NSCLC) according to the 9th edition of the AJCC/UICC NSCLC staging system;
Presence of lesions suitable for ablation therapy confirmed by imaging evaluation;
Evaluated as resectable with R0 resection before enrollment, and consent to undergo radical surgical resection;
Tumor is adjacent to the hilum, invades major blood vessels, or has contraindications for surgery;
History of interstitial lung disease, non-infectious pneumonia, or uncontrolled pulmonary diseases including pulmonary fibrosis and acute lung disease;
Previous allogeneic stem cell transplantation or organ transplantation;
Previous radiotherapy or chemotherapy;